NEW YORK, Nov. 30, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of National Beverage Corp. securities (NASDAQ:FIZZ) from July 16, 2015 through September 28, 2016, both dates inclusive (the “Class Period”) of the important December 5, 2016 lead plaintiff deadline in the class action filed by the firm. The lawsuit is seeking recovery of investor losses.
To join the National Beverage class action, go to http://www.rosenlegal.com/cases-958.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that National Beverage lacked effective internal controls over financial reporting due, in part, to undisclosed channeling of expenses through off book entities and undisclosed material related parties transactions. The lawsuit claims that as a result, defendants’ statements about National Beverage’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. On September 28, 2016, Glaucus Research Group published a report revealing these details for the first time. The lawsuit claims that investors suffered damages when these details entered the market.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 5, 2016. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-958.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 



